The fact that TNF inhibitors are often combined with methotrexate which also increases the risk for malignancy [37] and, in addition, the association of diseases treated with TNF inhibitors, for example, IBD or RA, with increased risk for cancer [38–41] is making the direct link between TNF inhibitors and malignancies harder to determine. The gene discussed is TNF; the disease is cancer.